Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion

Trial Profile

Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Topsalysin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors Sophiris Bio
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 May 2017 According to a Sophiris Bio media release, successful data from this proof-of-concept study of topsalysin, will be presented today as a poster at the 112th American Urological Association (AUA) Meeting (2017).
    • 15 May 2017 According Sophiris Bio media release, data from this trial presented at the 32nd European Association of Urology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top